Clene (CLNN) Lytham Partners Fall 2026 Investor Conference summary

Company overview and differentiators

• Offers the first oral nanotherapeutic suspension for neurodegenerative diseases, targeting ALS, MS, and Parkinson's with a proprietary gold nanocrystal asset, CNM-Au8.

• Focuses on the intersection of physics, material science, and biology to address unmet needs in ALS, a fatal disease with limited treatment options.

• CNM-Au8 is administered orally and is currently used in multiple clinical studies and expanded access protocols.

Clinical development and regulatory strategy

• CNM-Au8 missed its primary endpoint in the HEALEY study but demonstrated significant survival benefit and improvements in function and neurofilament biomarkers.

• Compiled extensive data for a new drug application, including survival, neurofilament response, and preservation of function and breathing capacity.

• Engaged in multiple meetings with the FDA, following agency guidance for data submission and statistical modeling.

• Plans to submit the new drug application at the start of Q4 2026, with potential FDA review and decision expected by mid-2027.

Commercial outlook and financial position

• If approved, expects to reach thousands of patients in the first year, generating revenue through insurance and government programs.

• Recently secured sufficient cash to fund operations through the FDA's decision on the new drug application.

• Highlights the potential for significant market cap appreciation if accelerated approval is granted.